Day One Biopharmaceuticals: A 2025 Revenue Jump, a January Acquisition, and a 2026 Forecast That Could Shift the Sector
What happened, succinctly (and with the ticker in mind)
Day One Biopharmaceuticals, trading under the DAWN ticker, reported robust 2025 net product revenue and signposted a concrete revenue trajectory for 2026. While the press release focuses on top-line momentum rather than a traditional earnings-per-share (EPS) narrative, readers will want to note the absence of disclosed EPS figures and how markets view EPS consensus versus the company’s revenue forecast for 2026. The zero-hero emphasis here is on sales momentum, patient access, and the pipeline that could turn momentum into durable cash flow.
Key numbers that matter
- Q4 2025 net product revenue: $52.8 million
- Full-year 2025 net product revenue: $155.4 million
- Full-year 2025 revenue strength described as 172% year-over-year growth, with double-digit sequential quarterly gains through the year
- Q4 2025 prescriptions: 1,394
- Full-year 2025 prescriptions: 4,635
- 2026 U.S. net product revenue forecast: $225–$250 million
Highlights, with a forward-looking tilt
The centerpiece remains OJEMDA, Day One’s flagship product, which is driving the current growth cadence. The company emphasizes not only current sales but momentum that it expects to carry into 2026, supported by the improving commercial footprint and ongoing interest in its pipeline. A cadence of growth is being projected even as the company expands through external complements and pipeline updates.
Around the same time, Day One disclosed an important strategic move: an January 2026 acquisition of Mersana Therapeutics, broadening the pipeline landscape and potentially accelerating value creation if synergy or complementary assets translate into additional revenue streams. The release also notes Emi-Le in Phase 1 for adenoid cystic carcinoma (ACC), signaling that Day One intends to parallel strong commercial progress with early-stage clinical momentum.
Event to watch
Day One plans to host a conference call and webcast on February 24, 2026, at 4:30 p.m. ET. In markets where timing matters, that call is effectively a checkpoint for whether investors should parlay 2025 momentum into a more aggressive 2026 outlook, or whether the forward-looking revenue forecast remains a best-idea, not a guarantee.
Voice from the bench: what the CEO said, and what it might portend
“2025 was a seminal year for Day One, marked by significant achievements across every pillar of our organization. By maintaining our strong commercial execution, leveraging our expertise to extend into additional rare cancers, and steadily advancing our early-stage pipeline, we are delivering on our mission to bring new medicines to people of all ages with life-threatening diseases,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “The commercial momentum we've established for OJEMDA and the important upcoming clinical data updates across our full pipeline position us for strong growth in 2026 and beyond.”
Analysis: what the numbers could portend for Day One and peers
The topline figures paint a convincing narrative of acceleration rather than a one-off sprint. The 172% YoY growth in net product revenue, coupled with a 4,635-person-year-long prescription figure in 2025, suggests Day One is moving past launch-stage volatility toward a more predictable revenue trajectory—an outcome that would elevate the stock’s multiple if the 2026 forecast proves durable. However, the structural stock market test remains: can the company convert this sales momentum into consistent earnings leverage, especially as we consider EPS and the elusive EPS consensus in the days ahead?
The Mersana acquisition adds a potential push into the late- or early-stage pipeline with strategic fit in rare cancers and new modality opportunities. If integration costs stay contained and the acquired assets unlock cross-sell or pivot into Day One’s commercial engine, the plan could yield more than just pipeline optionality. The risk, of course, is execution: pipeline assets require capital, regulatory clearance, and clinical readouts that may or may not align with the company’s timing. In the near term, the stock’s reaction will likely hinge on how investors calibrate the 2026 revenue forecast against any shift in the burn rate and capital allocation signal the Mersana deal implies.
For sector peers, the Day One narrative may raise the bar for early-stage biotech profitability expectations. If OJEMDA’s momentum is sustainable and the pipeline accelerates post-acquisition, rivals could be compelled to reprice expectations around revenue forecast and near-term profitability, rather than focusing solely on phase-1 or phase-2 readouts. The absence of disclosed EPS data leaves earnings surprise and EPS consensus discussions more speculative for now, but the implied message is clear: investors are prioritizing revenue growth quality, patient access, and pipeline optionality as a proxy for long-term value creation.
Bottom line: a Day One of building blocks for a bigger 2026
Day One Biopharmaceuticals is turning 2025 momentum into a forward-looking narrative anchored by a clear revenue forecast for 2026 and a strategic acquisition that could broaden its cash-flow runway. The absence of a reported EPS figure means the current narrative is about revenue trajectory and pipeline leverage rather than quarterly per-share metrics. For investors, the question now is how well the company can translate the Q4 and full-year growth into sustainable earnings power, and whether the Mersana deal unlocks additional growth avenues without overextending the balance sheet.
All eyes will be on the February 24 call, where leadership will attempt to translate this momentum into a credible path to 2026 targets. If Day One can maintain the pace and demonstrate progress on Emi-Le in ACC and any synergies from Mersana, the stock could transition from a momentum story to a more durable earnings narrative—an outcome that even Matt Levine might describe as a cautious, well-structured bet rather than a flashy headline. In the meantime, DAWN remains a name to watch for a sector that prizes pipeline clarity and revenue durability as much as it does flashy clinical readouts.